Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Curative-intent bests low-intensity and palliative treatment for elderly DLBCL patients

Publish date:: May 27, 2020

Key clinical point: Elderly DLBCL patients benefit from rituximab‐anthracycline‐based treatment given with curative intent.

Major finding: The 2‐year overall were better in patients aged ≥ 80 years given treatment with curative intent (54%) than low‐intensity (26%), or palliative treatment (6%).

Study details: Review of 1,194 patients aged ≥ 80 years diagnosed in Sweden 2007-2014.

Disclosures: The authors reported they had no conflicts of interest.

Citation:

Sonnevi K et al. British Journal of Haematology. 2020; doi.org/10.1111/bjh.16737.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in DLBCL

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,

Survey quantifies COVID-19’s impact on oncology,

Sarcopenia is a predictor of overall survival in DLBCL patients,

Mutation tied to central nervous system collapse in DLBCL,